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Abstract
Background: In women with abnormal uterine bleeding, fibroids are a frequent finding. In case of heavy menstrual
bleeding and presence of submucosal type 0–1 fibroids, hysteroscopic resection is the treatment of first choice, as
removal of these fibroids is highly effective. Hysteroscopic myomectomy is currently usually performed in the
operating theatre. A considerable reduction in costs and a higher patient satisfaction are expected when procedural
sedation and analgesia with propofol (PSA) in an outpatient setting is applied. However, both safety and effectiveness
– including the necessity for re-intervention due to incomplete resection – have not yet been evaluated.
Methods: This study is a multicentre randomised controlled trial with a non-inferiority design and will be performed in
the Netherlands. Women > 18 years with a maximum of 3 symptomatic type 0 or 1 submucosal fibroids with a
maximum diameter of 3.5 cm are eligible to participate in the trial. After informed consent, 205 women will be
randomised to either hysteroscopic myomectomy using procedural sedation and analgesia with propofol in an
outpatient setting or hysteroscopic myomectomy using general anaesthesia in a clinical setting in the operating theatre.
Primary outcome will be the percentage of complete resections, based on transvaginal ultrasonography 6 weeks
postoperatively. Secondary outcomes are cost effectiveness, menstrual blood loss (Pictorial blood assessment chart),
quality of life, pain, return to daily activities/work, hospitalization, (post) operative complications and re-interventions.
Women will be followed up to one year after hysteroscopic myomectomy.
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Discussion: This study may demonstrate comparable effectiveness of hysteroscopic myomectomy under procedural
sedation and analgesia versus general anaesthesia in a safe and patient friendly environment, whilst achieving a
significant cost reduction.
Trial registration: Dutch trial register, number NTR5357. Registered 11th of August 2015.
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Background
In women with abnormal uterine bleeding, fibroids are a
frequent finding. In case of heavy menstrual bleeding and
presence of submucosal type 0–1 fibroids, hysteroscopic
resection is the treatment of first choice, as removal of
these fibroids is highly effective [1]. Hysteroscopic myo-
mectomy is performed in an estimated 3000 women
annually in the Netherlands. In the literature, a reduction
of symptoms has been reported in 70–99% of the proce-
dures [1–6]. The wide range of this success rate reflects
the inclusion of all types of submucosal fibroids in the
studies, including type 2 submucosal fibroids of which re-
moval can be more complicated due to their extension
into the myometrium. In case of submucosal fibroids hys-
teroscopic myomectomy is recommended as first choice
treatment by the Dutch guideline on Heavy Menstrual
Bleeding [7].
In the last decades, there has been a trend in moving
hysteroscopic surgery from a clinical setting with general
or spinal anaesthesia to an outpatient setting. Especially
hysteroscopic surgery of smaller diameter polyps (< 2
cm) and low grade adhesions are eligible for resection in
an outpatient setting [8–10]. Even for smaller type 0 and
1 submucosal fibroids it has been reported that these
can be successfully removed in an outpatient setting
under local anaesthesia [11]. However, clinical setting is
still necessary for larger fibroids that generally require
the use of larger diameter instruments such as a resecto-
scope and hence the need of cervical dilatation up to 9
mm and general or spinal anaesthesia.
Procedural sedation and analgesia (PSA) is used for a
wide variety of interventional procedures in multiple set-
tings outside the operating theatre. In gynaecology, the
use of PSA has also become more popular since tech-
nical and instrumental improvements have significantly
increased the feasibility and acceptability of hysteroscopy
in outpatient setting [12, 13]. Until now, PSA for resec-
tion of fibroids is not commonly used.
A considerable cost reduction is expected when PSA
will be applied for hysteroscopic resection of fibroids:
the use of PSA means that hysteroscopic myomectomy
can be moved away from the operating theatre to an
outpatient setting. Hence less dedicated personnel is
needed. Other potential advantages of hysteroscopic
fibroid resection with PSA are avoidance of general
anaesthesia and its associated risks, a shorter recovery
time – resulting in a shorter hospital stay –, faster
return to mobility, full fitness and normal activities.
Finally, waiting lists for major surgery will be reduced
by averting the need for the operating theatre for
minor procedures.
Due to the abovementioned factors higher patient
satisfaction is also expected, as both hospital stay and
time-to-work are shorter and side effects of general
anaesthesia such as nausea are reduced.
The use of PSA seems to be feasible and well-tolerated
in gynaecological surgery [14–16]. However, there are no
randomised controlled trials (RCTs) available on the use
of PSA for hysteroscopic myomectomy. This RCT is the
first trial comparing the use of PSA for hysteroscopic
myomectomy with hysteroscopic myomectomy in a
clinical setting under general anaesthesia.
Methods
Objective
The aim of this study is to compare hysteroscopic resec-
tion of symptomatic type 0 and type I submucosal fi-
broids under procedural sedation and analgesia with
propofol in an outpatient setting with hysteroscopic
myomectomy in an inpatient clinical setting using
general anaesthesia. It is hypothesised that hysteroscopic
myomectomy with PSA is non-inferior to the same
procedure carried out under general anaesthesia. This
study will also compare the cost effectiveness, pain,
menstrual blood loss (pictorial blood assessment chart:
PBAC score), quality of life, return to daily activities/
work, hospitalization, (post) operative complications and
re-interventions.
Trial design and setting
This study is a multicentre randomised controlled trial
with a non-inferiority design. A cost-effectiveness study
will be performed together with the clinical study. The
study is embedded in the Dutch Consortium for Health-
care Evaluation and Research in Obstetrics and Gynaecol-
ogy. Participating hospitals are university and teaching
hospitals in the Netherlands. Women will be randomised
for hysteroscopic myomectomy either under general anaes-
thesia or procedural sedation and analgesia with propofol.
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Eligibility criteria
Inclusion criteria
The following women will be included:
– A minimum age of 18 years
– A maximum of 3 symptomatic type 0 and type 1
submucosal fibroids
– A maximum diameter of 3.5 cm (as diagnosed by
transvaginal ultrasonography)
– American Society of Anaesthiologists (ASA) class 1
or 2
– Sufficient knowledge of Dutch or English language
to fully understand the study and complete the
questionnaires
Exclusion criteria
– Presence of clotting disorders
– Severe anemia (Hb under 5.0 mmol/l)
– ASA class 3 or 4
Interventions
According to guidelines from the Health Care In-
spectorate (IGZ) and Dutch Institute for Healthcare
Improvement (CBO) Non-Anaesthesiologist Adminis-
tered Propofol (NAAP) sedation is given and moni-
tored by a qualified sedation practitioner [17, 18].
Non-invasive blood pressure, electrocardiogram and
oxygen saturation are measured before vascular access
is obtained. Propofol combined with short acting
intravenous analgesia is used for procedural sedation.
An experienced surgeon performs the hysteroscopic
resection by standard procedure with the use of a resec-
toscope or morcellation device in an office based setting.
Patients are observed after the procedure by qualified
personnel and discharged as soon as all the discharge
criteria are met, normally within 1 to 1.5 h.
General anaesthesia can be volatile based or total
intravenously, with the use of a laryngeal mask or tube.
Postoperatively, patients will be observed in the recovery
room and discharged home from clinic when all the
discharge criteria are met. Hysteroscopic myomectomy
is performed by standard procedure.
Outcome measures
Primary outcome measures
Primary outcome will be the percentage of complete
resections, evaluated by transvaginal ultrasonography
(TVU) (contrast sonography if TVU is inconclusive) 6
weeks postoperatively. The ultrasonography will be
performed by an independent gynaecologist or ultrason-
ographer blinded for the treatment arm and judgment of
completeness by the surgeon who performed the hyster-
oscopic myomectomy. This TVU should be conducted 6
weeks postoperatively. A complete resection means that
there are no signs of an intracavitary remaining of the
fibroid (s) resected during hysteroscopic myomectomy.
This follow-up visit and TVU is part of the current usual
care, so no extra ultrasonography is needed for study
purposes.
Secondary outcome measures
Secondary outcomes are cost effectiveness, pain,
menstrual blood loss (PBAC score), quality of life, return
to daily activities/work, hospitalization, (post) operative
complications, re-interventions. These secondary param-
eters will be assessed by several questionnaires.
Patient recruitment
The gynaecologist participating in the network will
inform women about the study and refer the eligible
women to dedicated research nurses if available. These
nurses or the local investigator will counsel women, ask
for written informed consent and perform randomisa-
tion to either PSA or general anaesthesia. The investi-
gators will also organize the required treatments,
depending on the result of the randomisation. Sub-
jects can leave the study at any time for any reason if
they wish to do so without any consequences. The
investigator can decide to withdraw a subject from
the study for urgent medical reasons.
Randomisation
Randomisation will be performed web based with the
use of a block design, with a variable block size.
Blinding
The study will not be double-blinded, as it is impossible
to blind the health care workers and women involved for
the strategy to which the woman is allocated. The
person performing the transvaginal ultrasonography at 6
weeks follow up, however, will be blinded for the study
arm and judgement of completeness by the surgeon
during the procedure.
Data collection
Women will be asked to complete questionnaires online,
through a link they receive by e-mail (it is possible to
complete the questionnaires on paper when women
prefer to do so).
A website dedicated to studies in the Dutch Consortium
for Healthcare Evaluation and Research in Obstetrics and
Gynaecology will be used for data collection. Research
nurses in each of the participating centres will perform
the data collection. A computer generated numeric code
– to which the key is only available to the local investiga-
tor or local research nurse–will be attributed to each par-
ticipant, enabling anonymous data management.
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In accordance with the guidelines of the Dutch Feder-
ation of University Medical Centers (NFU) the data will
be preserved for 15 years.
Women will be followed from baseline (pre-opera-
tively) up to 1 year after hysteroscopic myomectomy
(Fig. 1). During follow up the following data will be
collected and registered in a Case Record Form (CRF):
Baseline characteristics
At baseline, before treatment, the following character-
istics are registered: body mass index, medical history,
demographics, parity, age, type and number of fibroids.
Characteristics registered during and after the procedure
Completeness of resection as judged by surgeon,
surgical complications, anaesthesiologic complications
(desaturation, airway obstruction, dysrhythmias, blood
pressure drops, ECG alterations), operating time, intra-
vasation/fluid deficit, recovery time (time from end of
procedure until completely awake and communicative),
use of pain medication, pain intensity measured by NRS
scores, duration of hospitalization (hours).
Questionnaires
Participating women will fill in questionnaires at
baseline, which will be given before the surgical
procedure. During follow-up, women will fill in
questionnaires at 24 h, 2 weeks, 8 weeks, 6 and 12
months after randomisation (Table 1). Questionnaires
will contain:
– Short questionnaire on side effects 24 h after
surgery. See Additional files 1 and 2 for an example
of the Dutch and English version of this
questionnaire.
Fig. 1 Flowchart of study design
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– The EuroQoL (EQ-5D-5 L) questionnaire
(15 questions) to assess the quality of life [19].
– Pictorial Blood Assessment Chart (PBAC) scores
to assess the amount of menstrual blood loss.
See Additional files 3 and 4 for an example
of the Dutch and English version of this
questionnaire.
– Uterine Fibroid Symptoms – Quality of Life (UFS-
QoL) questionnaire (37 questions) to assess the
quality of life focussing on women suffering from
uterine fibroids [20]. See Additional file 5 for an
example of the Dutch version of this questionnaire.
– Recovery Index (RI-10) questionnaire (10 questions):
to assess a patients’ recovery process [21].
– Medical Consumption Questionnaire (iMCQ): for
cost effectiveness analysis [22].
– Productivity Cost Questionnaire (iPCQ) to assess
productivity loss [23].
– Short questionnaire on recurrence and re-
interventions at 12 months after surgery. See
Additional files 6 and 7 for an example of the
Dutch and English version of this questionnaire.
Monitoring
An independent Data Safety Monitoring Board (DSMB)
will be asked to monitor the progress of the study and
the safety of its participants. Accumulating data on
serious adverse events will be sent to the DSMB each
time data of serious adverse effects in 20 women has
been received. In addition, an overview of reported SAEs
will be send to the DSMB after each 50 women included
and operated during the study. The DSMB will meet as
required to review any expected adverse events and may
ask to review outcomes or other data that may have an
impact on the trial.
No formal interim analysis or efficacy will be done.
Statistical analysis
Sample size
The study is designed as a non-inferiority study, in which
we aim to investigate if hysteroscopic myomectomy under
procedural sedation with propofol is non-inferior to the
same surgical procedure under general anaesthesia. With
205 women randomized we have 90% power to demon-
strate non-inferiority, based on an estimated 2.5% incom-
plete resections in both groups, with an non-inferiority
upper limit of 10% incomplete resections defined as
non-inferior (i.e. a delta of 7.5%), an alpha of 0.025 and a
drop-out rate of 10%.
Data analysis
Data will be analysed according to the intention-to-treat
principle. We will also perform a per protocol analysis,
given the non-inferiority design of the study, where
crossover between the groups will increase the chances
of concluding non-inferiority, if in reality the treatment
is not inferior. We will present the percentage of
complete resections at 6 weeks in both groups, with
according relative risks and 95% confidence interval.
Differences will be tested with the Chi-square test, or, if
the expected cell count is low using the Fisher exact test.
We will also calculate the relative risk, adjusted for the
resection technique which was used. Stratification will
be performed by resection technique (resection or mor-
cellation). Complications during and after surgery, and
re-interventions will be categorized. The Data and Safety
Monitoring Board will evaluate serious adverse events.
Pain intensity after the procedure and at discharge will
be reported as means with SD, risk differences between
both groups will be calculated with according 95% confi-
dence interval. Time to recovery and pain will be visual-
ized in a graph, and analyzed using a mixed model, that
can take into account repeated measures in the same
woman over time. The quality of life and PBAC scores
will be analyzed according the developed algorithms. We
will perform a subgroup analysis for fibroid size (< 2 cm
versus ≥2 cm) and for parity (nulliparous versus multip-
arous women).
Economic evaluation
This economic evaluation aims to link the difference in
societal and healthcare costs to the difference in clinical
effects between PSA and general anaesthesia. A
cost-effectiveness and cost-utility analysis will be carried
Table 1 Questionnaires and exams at baseline and during follow up
Side effects, NRS EQ-5D-5 L PBAC UFS-QoL RI-10 iMCQ iPCQ Re-intervention TVU
Baseline X X X X
24 h X X X
2 weeks X X
6 weeks X
8 weeks X X X X X X
6months X X X
12 months X X X X X
van der Meulen et al. BMC Women's Health           (2019) 19:46 Page 5 of 7
out with a time horizon of 1 year. Thus, discounting is
not necessary. Costs will be measured from a societal
perspective using internet questionnaires based on the
iMCQ after 8 weeks, 6 and 12months of follow-up.
Direct costs consist of costs of primary and hospital care
as well as costs of complementary care and home care.
Indirect costs involve costs caused by being absent from
paid and unpaid work, or by presenteeism. Estimation of
indirect costs will be done by using the friction cost ap-
proach. The standard prices presented in the Dutch
costing guidelines [24] will be used to value health care
utilization and prices of the Royal Dutch Society for
Pharmacy [25] will be used to value medication use.
Societal costs will be related to the following effect
measures in the economic evaluation: percentage of
complete resections and quality-adjusted life-years
(QALYs) based on the Dutch tariff for the EuroQol
(EQ-5D-5 L) [26, 27]. The analysis will be done accord-
ing to the intention-to-treat principle. Missing cost and
effect data will be imputed using multiple imputation.
The difference in mean total costs between the two
groups will be divided by the difference in mean effects
in order to calculate the Incremental cost-effectiveness
ratios (ICERs). Estimation of 95% confidence intervals
around cost differences will be done by bootstrapping
with 5000 replications. This will also be used to estimate
the uncertainty around the ICERs, which will be demon-
strated on cost-effectiveness planes. Estimation of cost-ef-
fectiveness acceptability curves will be performed to
present the likelihood that the intervention is cost-effect-
ive compared to the current standard care for a spectrum
of different ceiling ratios [28]. .Adjustment for con-
founders and effect modifiers will be done if necessary.
Discussion
Fibroids are a frequent finding in women with abnormal
uterine bleeding. The Dutch Guideline ‘Heavy menstrual
bleeding’ recommends hysteroscopic myomectomy as
treatment of first choice in case of symptomatic submu-
cous fibroids [7]. In the current situation, women are
usually admitted into daycare and they are operated
under general anaesthesia. This requires an operating
theatre with a full anaesthetic team. Procedural sedation
has never been evaluated for hysteroscopic myomectomy
regarding both effectiveness (complete resection) and
cost-effectiveness. The Dutch guideline committee sug-
gests that local anaesthesia or ‘conscious sedation’ can be
taken into consideration for hysteroscopic myomectomy
based on indirect evidence from other areas in health-
care [7]. This non-inferiority RCT is the first trial about
hysteroscopic myomectomy for symptomatic type 0 or
I submucosal fibroids in an outpatient setting using
procedural sedation with propofol compared to the
current standard hysteroscopic myomectomy in day-
care using general anaesthesia. Several advantages are
expected when performing hysteroscopic myomec-
tomy under PSA compared to general anaesthesia.
Due to this study design and outcome measures, the
results will be applicable for a large group of women
suffering from abnormal uterine bleeding caused by
submucosal fibroids.
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